In 76 DGC samples, 10 of 29 E-cadherin-deficient tumours harboured somatic mutation or biallelic loss of TP53 gene, whereas 19 of 47 E-cadherin-intact tumours did, suggesting that E-cadherin/p53-deficiemt GC accounted for approximately 15% of DGC, and therefore was not rare (P = 0.636, Fisher’s exact test). Here, CDH1 is linked to neoplasm.